Taylor Julia, Krska Janet, Mackridge Adam
School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK.
Int J Pharm Pract. 2012 Oct;20(5):277-84. doi: 10.1111/j.2042-7174.2012.00190.x. Epub 2012 Mar 9.
To determine whether pharmacy-based cardiovascular disease (CVD) screening reached the desired population, the local population's awareness of pharmacy screening and the views of service users and the general public about CVD screening.
Pharmacy staff, located in one English Primary Care Trust providing a CVD screening service, issued questionnaires to service users who had undergone screening. Face-to-face street surveys were conducted with members of the general public within the vicinity of each participating pharmacy.
A total of 259 people were screened within the first 6 months of service provision, 97 of whom (37.4%) completed the evaluation questionnaire. In addition, 261 non-service users participated in street surveys. Most respondents among both service users and non-users had at least one risk factor for cardiovascular disease, including smoking and lack of exercise. Responses to statements regarding CVD screening showed a high level of agreement with the need for screening in both groups. However, significantly more service users (90.7%) agreed that a pharmacy was a good place for screening compared to the non-users (77.4%; P < 0.005). Likewise significantly fewer service users agreed that screening should be only carried out by doctors (10.3 compared to 25.3% of non-users; P < 0.005). The overall majority of service users 96 (99.7%) had a positive experience of the screening service, agreeing that they were given enough time and pharmacists made them feel at ease. Only 9% of non-users were aware of the pharmacy service and, although the majority (78.4%) were willing to be screened at a pharmacy, this was significantly lower among males than females (69.9 compared to 82.7%; P < 0.005). Perceived concerns about confidentiality and lack of privacy were among barriers identified to taking up screening.
Pharmacy-based CVD screening is acceptable to the public. Its uptake could be improved through increased awareness of the service and by addressing concerns about privacy and confidentiality in promotional activities.
确定基于药房的心血管疾病（CVD）筛查是否覆盖了目标人群、当地人群对药房筛查的认知以及服务使用者和公众对CVD筛查的看法。
位于一个提供CVD筛查服务的英国初级医疗信托机构的药房工作人员，向接受过筛查的服务使用者发放问卷。在每个参与的药房附近对公众进行面对面的街头调查。
在服务提供的前6个月内，共有259人接受了筛查，其中97人（37.4%）完成了评估问卷。此外，261名非服务使用者参与了街头调查。服务使用者和非使用者中的大多数受访者都至少有一项心血管疾病风险因素，包括吸烟和缺乏运动。对有关CVD筛查的陈述的回答显示，两组对筛查需求的认可度都很高。然而，与非使用者（77.4%）相比，明显更多的服务使用者（90.7%）认为药房是进行筛查的好地方（P < 0.005）。同样，明显更少的服务使用者认为筛查应该只由医生进行（10.3%，而非使用者为25.3%；P < 0.005）。总体而言，绝大多数服务使用者96人（99.7%）对筛查服务有积极体验，认为他们有足够的时间，药剂师让他们感到安心。只有9%的非使用者知道药房服务，尽管大多数（78.4%）愿意在药房接受筛查，但男性的意愿明显低于女性（69.9%对82.7%；P < 0.005）。对保密性和缺乏隐私的担忧被认为是接受筛查的障碍。
基于药房的CVD筛查为公众所接受。通过提高对该服务的认知以及在宣传活动中解决对隐私和保密性的担忧，可以提高其接受度。
